India, Oct. 14 -- Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company developing pelareorep, announced an update on its Phase 1/2 GOBLET study, including the expected timing of clinical data releases and receipt of the final payment under its grant from the Pancreatic Cancer Action Network (PanCAN).
Oncolytics expects to receive the final PanCAN grant payment later in the fourth quarter of 2026 following completion of certain activities in Cohort 5.
Patient enrollment in the cohort was completed earlier this year, marking the completion of a key phase of the study, although treatment and follow-up remain ongoing for some participants.
The GOBLET study is evaluating pelareorep-based combination therapies across multiple...